These studies confirm the beneficial effects of GLP-1 receptor agonists on glucose, insulin and lipid metabolism [29,30], and others also demonstrate their efficacy on hepatic parameters including plasma ALT, total liver volume and hepatic steatosis [13,14]. Here, INS is linked to fatty liver disease.